Momenta Pharmaceuticals, Inc. - News/Events - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

12/28/2017

Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference

11/01/2017

Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

11/01/2017

Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)

10/18/2017

Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast

10/02/2017

Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer

08/30/2017

Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference

08/02/2017

Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update

07/21/2017

Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar

07/19/2017

Momenta Pharmaceuticals Announces Date of Second Quarter 2017 Financial Results Conference Call and Webcast

06/07/2017

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference

06/01/2017

Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer

05/10/2017

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

05/02/2017

Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results

04/26/2017

Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference

04/18/2017

Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast

02/28/2017

Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference

02/21/2017

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results

02/17/2017

Momenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast

02/17/2017

Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer

02/17/2017

Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL

02/07/2017

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast

02/01/2017

Momenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference

01/31/2017

Momenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE® (glatiramer acetate injection) 40 mg/mL Litigation

01/06/2017

Momenta Provides Year-End 2016 Corporate Update

01/05/2017

Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors

01/03/2017

Momenta Pharmaceuticals to Webcast Presentation at the 35th Annual J. P. Morgan Healthcare Conference